Hussain S Y, Massil J H, Matta W H, Shaw R W, O'Brien P M
Academic Department of Obstetrics and Gynaecology, Royal Free Hospital Medical School, London, UK.
Gynecol Endocrinol. 1992 Mar;6(1):57-64. doi: 10.3109/09513599209081007.
Buserelin, a luteinizing hormone releasing hormone agonist was administered nasally in doses of 900 micrograms daily to inhibit the ovarian cycle. Of 16 patients recruited, ten completed the treatment. Daily symptoms were measured on the Visual Analogue Scale and Trigg's trend analysis utilized for the analysis. The peak severity of symptoms (ESAmax) and the maximum global scores (Gmax) reduced on buserelin treatment. The minimum global scores (Gmin) and the minimum score for each symptom (ESAmin) increased, suggesting worsening of underlying symptoms. The difference between ESAmax and ESAmin (ESAdelta) and Gmax and Gmin (Gdelta) were calculated to determine the degree of symptom change. The delta scores for symptoms of depression, bloatedness and breast symptoms, and Gdelta were significantly reduced (p less than 0.05) on buserelin, whilst the latter significantly worsened in the follow-up months. Side-effects may limit the place of buserelin in the long-term treatment of premenstrual syndrome, although combination of additional hormonal treatment may facilitate long-term treatment.
布舍瑞林，一种促黄体生成素释放激素激动剂，通过鼻腔给药，每日剂量为900微克，以抑制卵巢周期。在招募的16名患者中，10名完成了治疗。每日症状通过视觉模拟量表进行测量，并采用Trigg趋势分析进行分析。布舍瑞林治疗后，症状的峰值严重程度（ESAmax）和最大总体评分（Gmax）降低。最低总体评分（Gmin）和每种症状的最低评分（ESAmin）增加，提示潜在症状恶化。计算ESAmax与ESAmin之间的差异（ESAdelta）以及Gmax与Gmin之间的差异（Gdelta），以确定症状变化程度。布舍瑞林治疗后，抑郁、腹胀和乳房症状的delta评分以及Gdelta显著降低（p<0.05），而在随访的几个月中后者显著恶化。副作用可能会限制布舍瑞林在经前综合征长期治疗中的应用，尽管联合额外的激素治疗可能有助于长期治疗。
